ruxolitinib

FDA Drug Profile — JAKAFI, OPZELURA

Drug Details

Generic Name
ruxolitinib
Brand Names
JAKAFI, OPZELURA
Application Number
NDA202192
Sponsor
Catalent Pharma Solutions, LLC
NDC Codes
11
Dosage Forms
TABLET, CREAM
Routes
ORAL, TOPICAL
Active Ingredients
RUXOLITINIB, RUXOLITINIB PHOSPHATE

Indications and Usage

1 INDICATIONS AND USAGE LEQSELVI™ is indicated for the treatment of adult patients with severe alopecia areata. Limitations of Use LEQSELVI is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine, or other potent immunosuppressants. LEQSELVI is a Janus kinase (JAK) inhibitor indicated for the treatment of adults with severe alopecia areata. ( 1 ) Limitations of Use: LEQSELVI is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, cyclosporine or other potent immunosuppressants. ( 1 )